{
    "nctId": "NCT00049114",
    "briefTitle": "Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer",
    "officialTitle": "A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 62,
    "primaryOutcomeMeasure": "Pathological complete response in the breast",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n* Phase I (closed to accrual as of 1/19/04):\n\n  * Nonregional stage IV disease\n* Phase II:\n\n  * Locally advanced disease, according to AJCC staging criteria:\n\n    * Stage IIB\n    * Stage IIIA\n    * Stage IIIB\n    * Stage IIIC\n* At least 1 bidimensionally or unidimensionally measurable indicator lesion\n* Hormone receptor status:\n\n  * Not specified\n* Female\n* Performance status - ECOG 0-1\n* Performance status - Karnofsky 70-100%\n* Not specified\n* WBC at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin normal\n* AST/ALT no greater than 2.5 times upper limit of normal\n* Creatinine normal\n* Creatinine clearance at least 60 mL/min\n* LVEF normal\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* No other invasive malignancies within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No prior allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other agents used in the study (e.g., imidazoles or quinolones)\n* No ongoing or active infection\n* No other concurrent uncontrolled illness that would preclude study participation\n* No psychiatric illness or social situation that would preclude study compliance\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Not specified\n* Phase I (closed to accrual as of 1/19/04):\n\n  * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n  * No more than 1 prior adjuvant/neoadjuvant regimen and 1 prior regimen for metastatic disease\n  * Prior doxorubicin allowed provided the following are true:\n\n    * Used in adjuvant setting\n    * Cumulative dose was no greater than 240 mg/m\\^2\n    * At least 1 year between completion of adjuvant therapy and relapse\n* Phase II:\n\n  * No prior chemotherapy for locally advanced breast cancer\n* At least 1 week since prior tamoxifen or other selective estrogen receptor modulators for prevention or other indications (e.g., osteoporosis, ductal carcinoma in situ, or invasive breast cancer)\n* Phase I (closed to accrual as of 1/19/04):\n\n  * More than 4 weeks since prior radiotherapy\n* Phase II:\n\n  * No prior radiotherapy for locally advanced breast cancer\n* Not specified\n* No antacids within 2 hours of study drug administration\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent anticancer therapy\n* No other concurrent investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}